Drugs / SWI019
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06913608 | Mar 2026 | idiopathic inflammatory myopathy, systemic lupus erythematosus, systemic sclerosis | Calibr, a division of Scripps Research | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT04450069 | Aug 2020 → May 2024 | Burkitt lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma +3 | Calibr, a division of Scripps Research | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04488354 Background | Jan 2021 → Oct 2025 | Burkitt lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma +3 | Calibr, a division of Scripps Research | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SWI019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04450069 ↗ |
| Modality | Protein / enzyme biologic | “an anti-CD19 (cluster of differentiation antigen 19) antibody (SWI019, the switch, a biologic)” NCT04450069 ↗ |
| Route | Other | “CLBR001 + SWI019 is administered via infusion” NCT04450069 ↗ |
| Target | CD19 | “an anti-CD19 (cluster of differentiation antigen 19) antibody” NCT04450069 ↗ |